U.S. House GOP Conference Chair Elise Stefanik (N.Y.), the third highest-ranking House Republican, has issued a news release and tweeted about signing on as a sponsor of bipartisan legislation prohibiting pharmacy benefit managers (PBMs) and other third-party payers from paying
…
The federal government has started reviewing applications from individuals seeking to be the next Director of the U.S. Health Resources and Services Administration (HRSA) Office of Pharmacy Affairs (OPA), the unit within HRSA that oversees the 340B program. Tuesday, Sept.
…
The dispute with pharmaceutical firms over the use of contract pharmacies for 340B covered entities is the biggest crisis facing the program since its inception in the early 1990s, 340B Report Publisher and CEO Ted Slafsky tells “The Future of
…
President Biden announced last week that he plans to nominate public health expert Robert Otto Valdez to serve as U.S. Health and Human Services (HHS) Assistant Secretary for Planning and Evaluation (ASPE).
ASPE is the principal adviser to HHS on
…
North Carolina Gov. Roy Cooper (D) signed into law yesterday a bill that imposes greater oversight of pharmacy benefit managers and protects most categories of 340B entities from so called discriminatory reimbursement and contracting practices. Disproportionate share hospitals (DSH), children’s
…
Federal health officials “violated unambiguous statutory commands” in 2018 when they lowered lower Medicare Part B drug reimbursement rates for 340B hospitals by nearly 30% and their decision should be set aside, hospital groups and individual hospitals told the U.S.
…SPONSORED CONTENT by Jerry Buller
The challenges that ‘white bagging’ poses for patients and providers are gaining attention as more health plans mandate these policies. ‘White bagging’ disrupts traditional ‘buy-and-bill’ practices for provider-administered drugs, creating patient safety concerns, operational problems, and financial challenges for covered entities.
SPONSORED CONTENT by Kristin Fox-Smith and William Wood, Visante
Those of us actively engaged in the 340B Program are well aware of the scores of issues faced by participating hospitals and it’s not surprising since they account for an exceptionally large percentage of all HRSA audits. But, what about other types
…SPONSORED CONTENT
The devastating double-whammy of Medicare Part B payment cuts and COVID-19 has again highlighted the 340B program’s significance to hospital finance. Once relegated to the hospital’s basement pharmacy, the 340B program is increasingly a topic of boardroom and C-suite discussions.
In the latest episode of Omnicell’s The Future of Pharmacy podcast, learn
…
Eli Lilly and AstraZeneca are the latest drug makers to disclose they have received a subpoena from the Vermont attorney general’s office related to their denials of 340B ceiling prices on drugs shipped to contract pharmacies.
*Sign up for news summaries and alerts from 340B Report
